DWTX NASDAQ
Dogwood Therapeutics, Inc.
1W: +7.3%
1M: -41.1%
3M: +5.8%
YTD: -65.6%
1Y: -79.3%
3Y: -93.7%
5Y: -98.9%
$1.46
+0.03 (+2.10%)
Weekly Expected Move ±8.7%
$1
$1
$1
$2
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
10 relationships10
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2023-07-14
Earliest Filing
2026-01-13
Latest Filing
partner: 8
acquirer: 1
target: 1
Counterparties (Filed by DWTX)
10 relationshipsCompanies named in DWTX's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Maxim Group LLC | MMS | partner | Placement agent for the registered direct offering and concurrent private placement. | 2026-01-13 | View |
| Serpin Pharma Inc. | — | partner | Entered into an exclusive licensing agreement and registration rights agreement to grant a global license for SP16 in ex | 2025-09-29 | View |
| Rejuvenation Labs, Inc. | — | partner | Received shares of common stock and preferred stock as consideration for entering into the licensing and registration ri | 2025-09-29 | View |
| Tungsten Advisors | — | partner | Acted as financial advisor to the Company and received Series A-2 Preferred Stock as compensation; entered into stockhol | 2025-09-29 | View |
| Sealbond Limited | — | partner | Entered into a stockholder support agreement to vote shares in favor of specific issuance proposals and adjournment prop | 2025-09-29 | View |
| Sealbond Limited | — | partner | Party to the Registration Rights Agreement Amendment | 2025-03-12 | View |
| Sealbond Limited | — | acquirer | Parent company of Pharmagesic that entered into a Share Exchange Agreement with Virios Therapeutics, Inc. to acquire 100 | 2024-10-07 | View |
| Pharmagesic (Holdings) Inc. | — | target | Canadian corporation whose 100% of issued and outstanding common shares were acquired by Virios Therapeutics, Inc. in th | 2024-10-07 | View |
| CK Life Sciences Int'l., (Holdings) Inc. | — | partner | Listed entity on the Hong Kong Stock Exchange that was the indirect parent of Pharmagesic prior to the Combination. | 2024-10-07 | View |
| JonesTrading Institutional Services LLC | — | partner | Capital On Demand Sales Agreement agent for offering and selling shares | 2023-07-14 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-13 | Earnings Release; Exhibits | View | |
| 2026-06-17 | Bylaws Amendment; Shareholder Vote; Exhibits | View | |
| 2026-05-14 | Earnings Release; Exhibits | View | |
| 2026-03-26 | Regulation FD; Exhibits | View | |
| 2026-03-12 | Submission of Matters to a Vote of Security Holders; Financial Statements and Exhibits | View | |
| 2026-01-20 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2026-01-13 | Entry into Material Definitive Agreement; Termination of Material Definitive Agreement; Unregistered | Agreement | View |
| 2025-11-28 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-11-21 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-09 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-09-29 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Material Modifica | Agreement | View |
| 2025-08-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-02 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-06-24 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-05-08 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-04-03 | Other Events; Financial Statements and Exhibits | View | |
| 2025-03-31 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-14 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-03-12 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Material Modifica | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR